tiprankstipranks
Trending News
More News >

Prothena downgraded to Neutral from Overweight at Cantor Fitzgerald

Cantor Fitzgerald downgraded Prothena (PRTA) to Neutral from Overweight without a price target Prothena announced that birtamimab’s Phase 3 AFFIRM trial in AL amyloidosis failed to meet its primary survival endpoint or either of two secondary endpoints, the analyst tells investors in a research note. Cantor says the news is “not surprising,” as it viewed AFFIRM as a high-risk study, and “applauds” the decision by the company to review all business operations.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue